Search

Search Constraints

You searched for: Author/Creator Ping, Jerry

Search Results

1. Volumetric response quantified using T1 subtraction predicts long-term survival benefit from cabozantinib monotherapy in recurrent glioblastoma. Issue 10 (5th April 2018)

2. Ibrutinib Plus Rituximab Versus Placebo Plus Rituximab for Waldenström's Macroglobulinemia: Final Analysis From the Randomized Phase III iNNOVATE Study. Issue 1 (1st January 2022)

3. Phase II study of cabozantinib in patients with progressive glioblastoma: subset analysis of patients naive to antiangiogenic therapy. Issue 2 (14th August 2017)

4. Phase II study of cabozantinib in patients with progressive glioblastoma: subset analysis of patients with prior antiangiogenic therapy. Issue 2 (3rd October 2017)

5. Phase 1b/2 study of ibrutinib and lenalidomide with dose-adjusted EPOCH-R in patients with relapsed/refractory diffuse large B-cell lymphoma*. Issue 9 (29th July 2021)

6. The combination of ibrutinib and rituximab demonstrates activity in first‐line follicular lymphoma. (16th March 2020)

7. The iR2 regimen (ibrutinib plus lenalidomide and rituximab) for relapsed/refractory DLBCL: a multicentre, non-randomised, open-label phase 2 study. (February 2023)